- Home
- PGNY vs JANX Comparison
PGNY vs JANX Comparison
Compare PGNY & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGNY
- JANX
- Stock Information
- Founded
- PGNY 2008
- JANX 2017
- Country
- PGNY United States
- JANX United States
- Employees
- PGNY N/A
- JANX N/A
- Industry
- PGNY Misc Health and Biotechnology Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- PGNY Health Care
- JANX Health Care
- Exchange
- PGNY Nasdaq
- JANX Nasdaq
- Market Cap
- PGNY 1.8B
- JANX 1.6B
- IPO Year
- PGNY 2019
- JANX 2021
- Fundamental
- Price
- PGNY $22.76
- JANX $31.05
- Analyst Decision
- PGNY Buy
- JANX Strong Buy
- Analyst Count
- PGNY 9
- JANX 7
- Target Price
- PGNY $22.71
- JANX $94.29
- AVG Volume (30 Days)
- PGNY 1.3M
- JANX 969.3K
- Earning Date
- PGNY 05-08-2025
- JANX 05-06-2025
- Dividend Yield
- PGNY N/A
- JANX N/A
- EPS Growth
- PGNY N/A
- JANX N/A
- EPS
- PGNY 0.57
- JANX N/A
- Revenue
- PGNY $1,167,221,000.00
- JANX $10,588,000.00
- Revenue This Year
- PGNY $5.81
- JANX N/A
- Revenue Next Year
- PGNY $11.34
- JANX $250.58
- P/E Ratio
- PGNY $39.68
- JANX N/A
- Revenue Growth
- PGNY 7.22
- JANX 30.99
- 52 Week Low
- PGNY $13.39
- JANX $22.52
- 52 Week High
- PGNY $33.84
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- PGNY 57.78
- JANX 55.36
- Support Level
- PGNY $20.63
- JANX $27.93
- Resistance Level
- PGNY $22.96
- JANX $32.59
- Average True Range (ATR)
- PGNY 0.90
- JANX 1.97
- MACD
- PGNY 0.06
- JANX 0.74
- Stochastic Oscillator
- PGNY 88.38
- JANX 84.75
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.